Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients

NCT00667810 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
901
Enrollment
INDUSTRY
Sponsor class

Stopped The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical benefit. This decision was not based on any new safety concerns.

Conditions

Interventions

Sponsor

Pfizer